Frontiers in Molecular Biosciences (May 2023)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

  • Kunika Saini,
  • Smriti Sharma,
  • Yousuf Khan

DOI
https://doi.org/10.3389/fmolb.2023.1130625
Journal volume & issue
Vol. 10

Abstract

Read online

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical efficiency of currently available drugs based on DPP-4 inhibitors. The safety profiles as well as future directions including their potential application in improving COVID-19 patient outcomes have also been discussed in detail. This review also highlights the existing queries and evidence gaps in DPP-4 inhibitor research. Authors have concluded that the excitement surrounding DPP-4 inhibitors is justified because in addition to controlling blood glucose level, they are good at managing risk factors associated with diabetes.

Keywords